- Home
- BOE vs VALN Comparison
BOE vs VALN Comparison
Compare BOE & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOE
- VALN
- Stock Information
- Founded
- BOE 2005
- VALN 2012
- Country
- BOE United States
- VALN France
- Employees
- BOE N/A
- VALN N/A
- Industry
- BOE Trusts Except Educational Religious and Charitable
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BOE Finance
- VALN Health Care
- Exchange
- BOE Nasdaq
- VALN Nasdaq
- Market Cap
- BOE 634.0M
- VALN 510.7M
- IPO Year
- BOE N/A
- VALN 2021
- Fundamental
- Price
- BOE $10.88
- VALN $6.36
- Analyst Decision
- BOE
- VALN Strong Buy
- Analyst Count
- BOE 0
- VALN 3
- Target Price
- BOE N/A
- VALN $15.33
- AVG Volume (30 Days)
- BOE 166.1K
- VALN 14.9K
- Earning Date
- BOE 01-01-0001
- VALN 05-07-2025
- Dividend Yield
- BOE 7.30%
- VALN N/A
- EPS Growth
- BOE N/A
- VALN N/A
- EPS
- BOE N/A
- VALN N/A
- Revenue
- BOE N/A
- VALN $201,099,222.00
- Revenue This Year
- BOE N/A
- VALN $17.98
- Revenue Next Year
- BOE N/A
- VALN $26.61
- P/E Ratio
- BOE N/A
- VALN N/A
- Revenue Growth
- BOE N/A
- VALN 21.64
- 52 Week Low
- BOE $8.80
- VALN $3.62
- 52 Week High
- BOE $10.48
- VALN $9.50
- Technical
- Relative Strength Index (RSI)
- BOE 56.35
- VALN 46.37
- Support Level
- BOE $10.76
- VALN $6.25
- Resistance Level
- BOE $10.78
- VALN $6.65
- Average True Range (ATR)
- BOE 0.14
- VALN 0.30
- MACD
- BOE 0.06
- VALN -0.02
- Stochastic Oscillator
- BOE 87.39
- VALN 27.24
About BOE Blackrock Enhanced Global Dividend Trust of Beneficial Interest
Blackrock Enhanced Global Dividend Trust has an investment objective to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. Further, it focuses on investing in a portfolio of equity securities and utilizing an option writing to seek total return performance and enhance distributions.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.